Browse the evidence

High DHA fish oil supplementation (DHA > EPA) improves cardiovascular efficiency during submaximal exercise by lowering heart rate and improving heart rate variability, without negatively affecting endurance performance.

If you are looking to improve cardiovascular efficiency during moderate exercise, high DHA fish oil (where DHA exceeds EPA) may help lower your heart rate for a given workload. This does not necessarily make you faster (endurance performance was unaffected in some studies), but it may make exercise feel easier by reducing cardiac strain. Look for supplements with a DHA:EPA ratio greater than 1:1, dosed between 1-6g daily.

High DHA fish oil supplementation improves postprandial arterial stiffness and endothelial function, potentially reducing cardiovascular disease risk, whereas EPA alone may not provide the same postprandial benefit.

To support vascular health and reduce arterial stiffness after meals, choose a high DHA fish oil supplement (where DHA is higher than EPA). This may improve how your arteries handle the stress of a fatty meal. Standard fish oils with higher EPA may not offer this specific post-meal vascular benefit.

Impaired nighttime sleep (increased wake time) in healthy older adults is associated with elevated 24-hour plasma levels of Interleukin-6 (IL-6) and cortisol, with the association being significantly stronger in older adults than in young adults.

If you are an older adult experiencing fragmented sleep, your body may be producing higher levels of stress hormones (cortisol) and inflammatory markers (IL-6) during the day, which in turn worsen your sleep. This creates a cycle. Managing stress and inflammation may help break this cycle, rather than accepting poor sleep as an unavoidable consequence of aging.

Consuming 1 cup (150g) of blueberries daily for 6 months improves endothelial function and reduces arterial stiffness in adults with metabolic syndrome, independent of changes in insulin resistance.

If you have metabolic syndrome, eating one cup of blueberries every day for six months can improve your blood vessel health and stiffness, which lowers cardiovascular risk. However, this amount of blueberries will not improve your insulin resistance or blood sugar control, so it should be part of a broader strategy that includes managing insulin sensitivity.

In statin non-users with metabolic syndrome, consuming 1 cup of blueberries daily for 6 months significantly increases HDL cholesterol, HDL particle number, and apolipoprotein A-I levels.

If you have metabolic syndrome and are not taking statins, eating one cup of blueberries daily for six months may improve your HDL cholesterol and particle numbers. This benefit was not observed in those taking statins, suggesting medication may interfere with this specific dietary effect.

Infusion of PYY3-36 at supraphysiological doses (0.8 pmol/kg/min) significantly reduces energy intake in both lean and obese subjects, primarily through increased sympathoadrenal activity (thermogenesis and lipolysis), though this effect is accompanied by significant side effects like nausea.

Infusing PYY3-36 at high doses significantly cuts food intake, but it comes with a high cost of nausea and discomfort. The current delivery method (infusion) creates a narrow therapeutic window where effective doses cause significant side effects. Until administration methods can provide stable plasma levels without these peaks, this hormone is not a practical standalone solution for obesity management via this route.

Short-term carbohydrate deficiency (50% deficit for 5 days) reduces fasting hepatic glucose production (HGP) and improves the sensitivity of HGP to suppression by insulin, leading to increased fat oxidation.

Reducing carbohydrate intake for several days lowers your liver's glucose output and makes your body more sensitive to insulin. This metabolic shift encourages your body to burn fat for energy instead of glucose.

Short sleep duration (e.g., 5 hours vs 8 hours) causes hormonal shifts (lower leptin, higher ghrelin) and elevated cortisol that increase appetite and abdominal fat deposition, thereby promoting obesity.

Prioritize getting 7-9 hours of sleep. Short sleep duration directly alters hunger hormones (lowering satiety signals like leptin and raising hunger signals like ghrelin) and increases cortisol, which drives cravings for high-fat, high-sugar foods and abdominal fat storage. Fixing sleep is a primary lever for weight management.

Roux-en-Y gastric bypass surgery reduces long-term dietary fat intake and preference for high-fat foods in humans and rats, likely mediated by conditioned taste aversion and elevated postprandial GLP-1 levels.

For patients undergoing gastric bypass, the surgery not only restricts stomach size but also biologically reduces the desire for high-fat foods. This is driven by increased gut hormones (GLP-1, PYY) and conditioned taste aversion, where high-fat meals may cause mild discomfort, leading to a natural shift toward lower-fat diets. This physiological shift supports long-term weight maintenance.

Short sleep duration (less than 6 hours per night) is associated with increased body mass index (BMI) and obesity risk, with a stronger and more consistent association observed in children and young adults compared to older adults.

Prioritize getting at least 7-8 hours of sleep per night. If you are struggling with weight management, especially if you are younger, insufficient sleep may be driving your hunger hormones (ghrelin/leptin) to increase appetite and cravings. Consistent sleep duration is as important for weight control as diet and exercise.

Short-term sleep restriction (typically <6 hours/night) increases vulnerability to obesity by dysregulating appetite hormones (lowering leptin, raising ghrelin) and increasing subjective hunger and caloric intake, particularly from high-calorie carbohydrates.

Prioritize getting 7-9 hours of sleep. If you are consistently sleeping less than 6 hours, you are biologically predisposed to eat more, especially high-calorie carbs, due to hormonal shifts. Fixing sleep may be as important for weight management as diet and exercise.

Short sleep duration (<6 hours/night) is associated with an increased risk of developing type 2 diabetes and hypertension, independent of obesity, through mechanisms involving impaired glucose tolerance and insulin resistance.

Aim for 7-9 hours of sleep to protect your metabolic health. Chronic short sleep is linked to a higher risk of developing type 2 diabetes and high blood pressure, even if you maintain a healthy weight. Prioritizing sleep is a key preventive health strategy.

Initiating hormone replacement therapy (HRT) with conjugated equine estrogens (CEE) after established cardiovascular disease or significant years post-menopause fails to provide cardiovascular protection and may increase early adverse events, whereas initiating therapy with estradiol near the time of menopause in healthy women can slow atherosclerosis progression.

If considering hormone therapy for cardiovascular health, the timing is critical. Starting estrogen therapy shortly after menopause in healthy women may slow atherosclerosis, but starting it years later in women with existing heart disease (especially using conjugated equine estrogens) does not protect the heart and may increase early risk. The type of estrogen matters: estradiol appears more effective than CEE in slowing plaque progression in healthy women.

Post-menopausal women exhibit 'anabolic resistance' to bone-loading exercise due to estrogen depletion, resulting in negligible increases in bone mass, although exercise can still preserve bone strength and mitigate loss.

If you are post-menopausal, do not expect exercise to significantly increase your bone density due to hormonal changes. However, continue weight-bearing and resistance exercise to maintain bone strength, improve balance, and reduce fracture risk. Focus on preservation and strength rather than mass gain.

Continuous Glucose Monitoring (CGM) metrics, specifically Time in Range (TIR) and Glycemic Variability (GV), provide superior clinical insight and safety compared to HbA1c alone by detecting hypoglycemia and glucose excursions that HbA1c misses.

If you have diabetes, rely on CGM data (Time in Range) alongside HbA1c. HbA1c tells you the average, but CGM shows the dangerous swings and lows that average numbers hide. Use this data to adjust diet and medication to stay in the 70-180 mg/dL range as much as possible.

Newer glucose-lowering agents (ultra-long-acting insulin analogs, SGLT2 inhibitors, GLP-1 RAs) reduce Glycemic Variability (GV) and hypoglycemia risk compared to older agents (e.g., insulin glargine 100U/mL) due to smoother pharmacodynamic profiles.

If you experience high glucose swings or frequent lows on older insulin, discuss switching to newer analogs (like Degludec or Glargine 300U) or adding SGLT2/GLP-1 agents with your doctor. These drugs are designed to work more smoothly, reducing dangerous lows and glucose spikes.

Glycemic Variability (GV), defined by a coefficient of variation (CV) >36%, is independently associated with an increased risk of hypoglycemia and diabetes-related complications, regardless of HbA1c levels.

Monitor your Glucose Coefficient of Variation (CV). If your CV is above 36%, your glucose is swinging too much, which increases complication risk. Work with your doctor to smooth out these swings using diet, exercise, or medication adjustments, even if your HbA1c looks okay.

Medium-term supervised exercise (12 weeks) in overweight/obese individuals increases fasting acylated ghrelin (AG) and subjective hunger, indicating an orexigenic drive, but simultaneously improves postprandial satiety efficiency through enhanced suppression of AG and increased late-phase GLP-1 release.

If you start a moderate-intensity exercise program (like brisk walking or jogging at 75% max heart rate) 5 days a week for 3 months, expect to feel hungrier when you wake up or between meals. This is a normal hormonal response (increased ghrelin). However, this hunger is counterbalanced by your body becoming more efficient at signaling fullness after you eat. Focus on the post-meal satiety benefits rather than fearing the fasting hunger, as this may help you maintain a calorie deficit more sustainably than dieting alone.

Ingestion of carbohydrates, proteins, and lipids stimulates enteroendocrine cells (EECs) to secrete gut hormones (GLP-1, GIP, CCK, PYY) via specific nutrient-sensing receptors and transporters, which modulates glucose homeostasis, appetite, and gastrointestinal motility.

Your gut naturally releases hormones like GLP-1 and PYY when you eat, which help regulate blood sugar and make you feel full. Eating a balanced diet with carbohydrates, proteins, and fats triggers this system. Artificial sweeteners do not trigger this response as effectively as real food.

Visceral adipose tissue accumulation is causally linked to hepatic insulin resistance and increased cardiometabolic risk, whereas subcutaneous adipose tissue accumulation is metabolically protective.

Prioritize strategies that promote subcutaneous fat storage (like lower-body resistance training) over those that might increase visceral fat. Monitor waist circumference and metabolic markers (blood sugar, lipids) rather than just total body weight, as visceral fat is the primary driver of metabolic disease.

Visceral adipose tissue promotes insulin resistance through the Portal Theory, where NEFAs and cytokines drain directly to the liver, whereas subcutaneous fat drains systemically and is diluted.

Targeting visceral fat loss is critical for metabolic health because this fat sends harmful signals directly to the liver. Exercises that reduce visceral fat (like aerobic exercise) may have outsized benefits for insulin sensitivity compared to exercises that only affect subcutaneous fat.

High consumption of fructose (specifically high-fructose corn syrup) promotes the development of nonalcoholic fatty liver disease (NAFLD) by driving hepatic de novo lipogenesis and inducing insulin resistance through JNK activation.

To protect your liver from fatty liver disease, limit your intake of added sugars, particularly those containing high-fructose corn syrup (HFCS) found in soft drinks and processed foods. The liver processes fructose uniquely, converting it directly into fat and causing inflammation, regardless of its effect on blood sugar.

Chronic hyperglycemia, indicated by elevated HbA1c levels, is associated with persistently lower muscle strength and muscle quality in aging adults, independent of muscle mass loss.

If you have elevated blood sugar levels (even if not yet diagnosed as diabetes), prioritize glycemic control not just for organ health, but to preserve muscle strength. This study suggests that high blood sugar directly harms muscle function, independent of how much muscle you have. Focus on managing blood glucose through diet and lifestyle to maintain mobility and reduce disability risk as you age.

Daily subcutaneous administration of the dual GLP-1/glucagon receptor agonist MEDI0382 produces superior weight loss and fat mass reduction in diet-induced obese mice and cynomolgus monkeys compared to the GLP-1 analogue liraglutide, driven by glucagon receptor-mediated increases in energy expenditure.

For individuals seeking significant weight loss and metabolic improvement, dual GLP-1/glucagon receptor agonists like MEDI0382 offer superior fat loss compared to GLP-1-only treatments. This is achieved through daily subcutaneous injections that leverage both satiety signals (GLP-1) and increased energy expenditure (glucagon). While effective in animal models, human clinical application requires medical supervision due to the hormonal nature of the intervention.